Diagnostic potential of tumor DNA from ovarian cyst fluid

Yuxuan Wang; Karin Sundfeldt; Constantina Mateoiu; Ie Ming Shih; Robert J. Kurman; Joy Schaefer; Natalie Silliman; Isaac Kinde; Simeon Springer; Michael Foote; Björg Kristjansdottir; Nathan James; Kenneth W. Kinzler; Nickolas Papadopoulos; Luis A. Diaz; Bert Vogelstein

doi:10.7554/eLife.15175

Diagnostic potential of tumor DNA from ovarian cyst fluid

Yuxuan Wang, Karin Sundfeldt, Constantina Mateoiu, Ie Ming Shih, Robert J. Kurman, Joy Schaefer, Natalie Silliman, Isaac Kinde, Simeon Springer, Michael Foote, Björg Kristjansdottir, Nathan James, Kenneth W. Kinzler, Nickolas Papadopoulos, Luis A. Diaz, Bert Vogelstein^*

^*Corresponding author for this work

Research output: Contribution to journal › Journal Article › peer-review

29 Scopus citations

Abstract

We determined whether the mutations found in ovarian cancers could be identified in the patients’ ovarian cyst fluids. Tumor-specific mutations were detectable in the cyst fluids of 19 of 23 (83%) borderline tumors, 10 of 13 (77%) type I cancers, and 18 of 18 (100%) type II cancers. In contrast, no mutations were found in the cyst fluids of 18 patients with benign tumors or non- neoplastic cysts. Though large, prospective studies are needed to demonstrate the safety and clinical utility of this approach, our results suggest that the genetic evaluation of cyst fluids might be able to inform the management of the large number of women with these lesions.

Original language	English
Article number	e15175
Journal	eLife
Volume	5
Issue number	2016JULY
DOIs	https://doi.org/10.7554/eLife.15175
State	Published - 15 07 2016
Externally published	Yes

Bibliographical note

Publisher Copyright:
© Wang et al.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.7554/eLife.15175

Cite this

@article{7b89b3c7ba354b578f15fb5f3138d0fd,

title = "Diagnostic potential of tumor DNA from ovarian cyst fluid",

abstract = "We determined whether the mutations found in ovarian cancers could be identified in the patients{\textquoteright} ovarian cyst fluids. Tumor-specific mutations were detectable in the cyst fluids of 19 of 23 (83\%) borderline tumors, 10 of 13 (77\%) type I cancers, and 18 of 18 (100\%) type II cancers. In contrast, no mutations were found in the cyst fluids of 18 patients with benign tumors or non- neoplastic cysts. Though large, prospective studies are needed to demonstrate the safety and clinical utility of this approach, our results suggest that the genetic evaluation of cyst fluids might be able to inform the management of the large number of women with these lesions.",

author = "Yuxuan Wang and Karin Sundfeldt and Constantina Mateoiu and Shih, \{Ie Ming\} and Kurman, \{Robert J.\} and Joy Schaefer and Natalie Silliman and Isaac Kinde and Simeon Springer and Michael Foote and Bj{\"o}rg Kristjansdottir and Nathan James and Kinzler, \{Kenneth W.\} and Nickolas Papadopoulos and Diaz, \{Luis A.\} and Bert Vogelstein",

note = "Publisher Copyright: {\textcopyright} Wang et al.",

year = "2016",

month = jul,

day = "15",

doi = "10.7554/eLife.15175",

language = "英语",

volume = "5",

journal = "eLife",

issn = "2050-084X",

publisher = "eLife Sciences Publications Ltd",

number = "2016JULY",

}

TY - JOUR

T1 - Diagnostic potential of tumor DNA from ovarian cyst fluid

AU - Wang, Yuxuan

AU - Sundfeldt, Karin

AU - Mateoiu, Constantina

AU - Shih, Ie Ming

AU - Kurman, Robert J.

AU - Schaefer, Joy

AU - Silliman, Natalie

AU - Kinde, Isaac

AU - Springer, Simeon

AU - Foote, Michael

AU - Kristjansdottir, Björg

AU - James, Nathan

AU - Kinzler, Kenneth W.

AU - Papadopoulos, Nickolas

AU - Diaz, Luis A.

AU - Vogelstein, Bert

PY - 2016/7/15

Y1 - 2016/7/15

N2 - We determined whether the mutations found in ovarian cancers could be identified in the patients’ ovarian cyst fluids. Tumor-specific mutations were detectable in the cyst fluids of 19 of 23 (83%) borderline tumors, 10 of 13 (77%) type I cancers, and 18 of 18 (100%) type II cancers. In contrast, no mutations were found in the cyst fluids of 18 patients with benign tumors or non- neoplastic cysts. Though large, prospective studies are needed to demonstrate the safety and clinical utility of this approach, our results suggest that the genetic evaluation of cyst fluids might be able to inform the management of the large number of women with these lesions.

AB - We determined whether the mutations found in ovarian cancers could be identified in the patients’ ovarian cyst fluids. Tumor-specific mutations were detectable in the cyst fluids of 19 of 23 (83%) borderline tumors, 10 of 13 (77%) type I cancers, and 18 of 18 (100%) type II cancers. In contrast, no mutations were found in the cyst fluids of 18 patients with benign tumors or non- neoplastic cysts. Though large, prospective studies are needed to demonstrate the safety and clinical utility of this approach, our results suggest that the genetic evaluation of cyst fluids might be able to inform the management of the large number of women with these lesions.

UR - https://www.scopus.com/pages/publications/84979544164

U2 - 10.7554/eLife.15175

DO - 10.7554/eLife.15175

M3 - 文章

C2 - 27421040

AN - SCOPUS:84979544164

SN - 2050-084X

VL - 5

JO - eLife

JF - eLife

IS - 2016JULY

M1 - e15175

ER -

Diagnostic potential of tumor DNA from ovarian cyst fluid

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this